Digital & Data
For more than 20 years, Roche and Genentech have been at the forefront of applying digital technologies and data to enhance our groundbreaking research and development of innovative treatments.
Now we are working to truly integrate the use of digital and data into the fabric of our R&D to bring the next generation of truly innovative treatments to patients. Our digital and data partnering strategy is built around identifying strategic partners with whom we can pursue this vision. With integration of new digital tools and AI across the Roche Group, we are working in new ways to shape the next generation of treatments.
Partnering opportunities we are looking for:
We are interested in collaborations on real world data, advanced analytics, digital tools and platform opportunities that:
- Enable infrastructure to train new AI models
- Expand our portfolio (novel targets, line extensions, combinations, etc.)
- Improve PTS and cycle times
- Increase product potential
Example partnerships
The Alan Turing Institute – Global partnership to generate insights into disease, patient, and outcome heterogeneity using advanced analytics.
Flatiron – Roche Group acquisition to advance use of real-world evidence in regulatory decision-making and at point of care.
Foundation Medicine (FMI) – Roche Group acquisition to further develop FMI's comprehensive genomic profiling platform and support the Roche Group’s PHC strategy.
NVIDIA – Partnership to accelerate R&D by using AI and computing technology to better understand disease biology and develop novel therapeutics.
Our Future Health – UK-based consortium to support one of the world's largest health programmes to enable research into the early diagnosis, prevention and treatment of diseases.
Together 4 CHANGE – Founding member of consortium to create a unique genomic data set for people of African ancestry to enhance ability to discover treatments for diverse populations.
Explore collaboration opportunities
Connect with our partnering experts to start the conversation.
